Floatz logo

Pembrolizumab

Recurrent Medulloblastoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

41 Active assets in the Recurrent Medulloblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Pfizer
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 2B
ETOPOSIDE
Theodore S. Johnson
Phase 2B
Cyclophosphamide
Theodore S. Johnson
Phase 2B

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →